Asset Details
Do you wish to reserve the book?
Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study
Do you wish to request the book?
Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study
2008
Overview
Axitinib (AG-013736) is a potent and selective oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, which have an important role in pancreatic cancer. The aim of this study was to assess the safety and efficacy of gemcitabine plus axitinib versus gemcitabine alone.
Between January and August, 2006, 103 patients with unresectable, locally advanced, or metastatic pancreatic cancer were randomly assigned in a two to one ratio to receive gemcitabine (1000 mg/m
2) plus axitinib 5 mg twice daily (n=69) or gemcitabine (1000 mg/m
2) alone (n=34) by a centralised registration system. The primary endpoint was overall survival. Analyses were done by intention to treat. This trial is registered with
ClinicalTrials.gov, number
NCT00219557.
All randomised patients were included in the efficacy analyses. Median overall survival was longer with gemcitabine plus axitinib than with gemcitabine alone (6·9 [95% CI 5·3–10·1] months
vs 5·6 [3·9–8·8] months). The hazard ratio for survival with gemcitabine plus axitinib versus with gemcitabine alone, adjusted for stratification factors, was 0·71 (95% CI 0·44–1·13). The most common grade 3 or worse adverse events were fatigue (15 [22%] patients in the gemcitabine plus axitinib group
vs one [3%] in the gemcitabine alone group), abdominal pain (eight [12%]
vs five [16%]), and asthenia (eight [12%]
vs one [3%]).
Gemcitabine plus axitinib showed a similar safety profile to gemcitabine alone; the small, non-statistically significant gain in overall survival needs to be assessed in a randomised phase III trial.
Pfizer Inc.
Publisher
Elsevier Ltd,Elsevier Limited
Subject
/ Aged
/ Antimetabolites, Antineoplastic - adverse effects
/ Antimetabolites, Antineoplastic - therapeutic use
/ Deoxycytidine - adverse effects
/ Deoxycytidine - analogs & derivatives
/ Deoxycytidine - therapeutic use
/ Female
/ Humans
/ Imidazoles - administration & dosage
/ Imidazoles - adverse effects
/ Imidazoles - therapeutic use
/ Indazoles - administration & dosage
/ Male
/ Pancreatic Neoplasms - drug therapy
/ Pancreatic Neoplasms - mortality
/ Pancreatic Neoplasms - pathology
/ Patients
/ Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors
/ Studies
/ Survival
